ALERT: ANTI-COMPETITIVE PRACTICE - PATENT - ANNULMENT - LICENSING AGREEMENT - ARBITRATION - PRELIMINARY RULING

Patents : Advocate General Melchior Wathelet invites the Court of Justice of the European Union to rule that article 101 TFUE does not prohibit licensing agreements under which the licensee has to pay fees until the termination of the agreement even if the related patent becomes is declared invalid, as long as the agreement’s objective is to ensure that the licensee can use the relevant technology without any risk of litigation relating to the patent and as the licensee may terminate the agreement after a reasonable period of notice (Genentech / Hoechst / Sanofi-Aventis)

Le 17 mars 2016, l'avocat général Melchior Wathelet a présenté ses conclusions dans l'affaire C-567/14 (Genentech Inc. / Hoechst GmbH, anciennement Hoechst AG, Sanofi-Aventis Deutschland GmbH). Il s'agit d'une demande de décision préjudicielle présentée par la Cour d'appel de Paris le 9 décembre 2014. Cette affaire s'inscrit dans le cadre d’un recours en annulation des sentences arbitrales opposant Genentech Inc., société de droit du Delaware, aux sociétés pharmaceutiques Hoechst et Sanofi-Aventis. En 1992, la société allemande Behringwerke AG a concédé à Genentech une licence non exclusive mondiale pour l’utilisation d'un activateur permettant d’accroître l’efficacité du processus cellulaire utilisé pour la fabrication de protéines. Cette technologie avait fait l’objet du brevet européen, puis de deux

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Patents : Advocate General Melchior Wathelet invites the Court of Justice of the European Union to rule that article 101 TFUE does not prohibit licensing agreements under which the licensee has to pay fees until the termination of the agreement even if the related patent becomes is declared invalid, as long as the agreement’s objective is to ensure that the licensee can use the relevant technology without any risk of litigation relating to the patent and as the licensee may terminate the agreement after a reasonable period of notice (Genentech / Hoechst / Sanofi-Aventis), 17 March 2016, Concurrences Review N° 2-2016, Art. N° 79624, www.concurrences.com

Visites 135

All reviews